The European Union has invested 30 million euros ($40.3 million) to understand the epigenome - a link between genes, environment and health. BLUEPRINT, a new large-scale research project, will lead to targeted diagnostics, new treatments and preventive measures for specific diseases in individual patients; an approach known as “personalized medicine.”
BLUEPRINT, officially launched on October 1, is the European cornerstone of an international research cooperation effort - the International Human Epigenome Consortium (IHEC), bringing together organizations and researchers from across the globe. The project upholds the EU's pledge to maximize open access to results of publicly-funded research, as teams from around the world will have a platform to openly share their results.
Maire Geoghegan-Quinn, European Commissioner for Research and Innovation, said: "Our genes may produce the ingredients that make us who and what we are, but it is the recipe - or epigenetics - that determines how those ingredients are put together. Europe is showing leadership in medical research with this groundbreaking international project that will improve prevention, diagnosis and treatment of disease."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze